At 9.1% CAGR 3D Printed Drugs Market Hits US$57.03 million by 2027 Says, The Insight Partners

According to The Insight Partners market research study titled “3D Printed Drugs Market Forecast to 2027 - Covid-19 Impact and Global Analysis by Dosage Forms and Technology,” the global 3D printed drugs market is expected to reach US$ 57.03 Mn in 2027 from US$ 28.52 Mn in 2019. The market is estimated to grow at a CAGR of 9.1% from 2020 to 2027. The report provides trends prevailing in the 3D printed drug ecosystem, and the driving factors and restraining factors pertaining to the market.

3D printed drugs are medications, which are designed by 3D printing technique to customize for the individuals in a safer and effective way. These drugs have unitary porous structures that readily disperse in the mouth, because of which these high-dose medicines need not to be swallowed intact. The main idea behind 3D printing drugs is to design and develop medicines that are suited to an individual's needs. The global 3D printed drugs market is driven by factors such as increasing adoption of personalized drugs. Additionally, growing research and development activities, coupled with increasing prevalence of dysphagia, is also anticipated to drive the 3D market growth during the forecast period. However, the usage of 3D printing to develop illegal drugs restrains the growth of the market. The developing healthcare infrastructure and increasing awareness regarding 3D printing in pharmaceuticals generate lucrative opportunities for the growth of the market.

Request for sample pages on 3D Printed Drugs Market at:

3D Printed Drugs Market: Competition Landscape and Key Developments

Leading companies operating in the 3D printed drugs market are Aprecia Pharmaceuticals, LLC, FabRx Ltd, Cycle Pharmaceuticals, GlaxoSmithKline PLC., Astrazeneca, Tvasta, and Merck KGGA, among others.

Increasing Adoption of Personalized Drugs

Personalized medicine is a growing area of treatment that relies on specific drug delivery and dosing. As per a study published by PMC, personalized medicines accounted for only 5% of the new FDA approved molecular entities in 2005; whereas, in 2016, they accounted for more than 25%. Additionally, 42% of all compounds and 73% of oncology compounds in the pipeline have the potential to be personalized medicines. Moreover, biopharmaceutical companies nearly doubled their R&D investment in personalized drugs over the past five years, and expect to increase their investment by 33% in the next five years. Biopharmaceutical researchers also predict a 69% increase in the number of personalized medicines in development over the coming five years.

3D printing offers the possibility of creating a personalized medicine system through automated control over drug dose and is suitable for both low and high drug concentrations. These advantages allow drug companies to not only boost efficacy and adherence, but also contribute to their brand longevity by expanding and capturing market share with other dosage forms. Through this breakthrough method of manufacturing and its fast-melt capabilities, there is an ability to overcome several obstacles, thereby contributing to better patient outcomes in the solid dose market. For instance, FabRx Ltd. completed the world’s first in-human clinical study using their proprietary Printlets technology, which relies on personalized 3D printed dosage forms to treat children with a rare metabolic disease. Additionally, the same company launched the first pharmaceutical 3D printer, M3DIMAKER, for the manufacture of personalized medicines in April 2020. Hence, there is a need for new manufacturing systems to prepare personalized medicines, and this potential application of 3D printing for rare diseases is countless. It could help make the medication safer and more attractive to children, thereby propelling the growth of the 3D printed drugs market.

3D Printed Drugs Market: Segmental Overview

The global 3D printed drugs market, based on the dosage forms, is segmented into tablets, capsules, multi drug implant, nanoparticles, solutions, and other dosage forms. The tablet segment held the largest share of the market in 2019, and it is further estimated to register the highest CAGR during the forecast period. The growth of the 3D printed drugs market is ascribed to the growing emphasis on personalized medicines and extensive R&D activities.

Based on technology, the 3D printed drugs market is segmented into inkjet printing, direct write, zip dose, thermal inkjet printing, fused deposition modelling, powder bed printing, stereo lithography (SLA), and semi-solid extrusion (SSE). The zip dose technology segment held the largest share of the market; moreover, it is expected to register the highest CAGR during the forecast period.

3D Printed Drugs Market– By Geography

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • UK
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • South Korea
    • Japan
    • Australia
    • Rest of Asia Pacific
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Buy Copy of 3D Printed Drugs Market Research Study at:

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:


Phone: +1-646-491-9876

Back to news